Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,761.00
Bid: 1,757.50
Ask: 1,758.00
Change: 27.50 (1.59%)
Spread: 0.50 (0.028%)
Open: 1,736.00
High: 1,767.00
Low: 1,736.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sunday newspaper round-up: HMRC's new tax deals, Tesco's debt, Sainsbury's

Sun, 24th Jan 2016 16:11

(ShareCast News) - In the wake of Google's £130m tax settlement with the UK taxman, other giant US corporations are close to shaking hands on their own deals. HM Revenue & Customs officials have confirmed to the Sunday Times that Amazon, Facebook, Microsoft and McDonald's are all close to agreements that would swell the national coffers but are likely to land the office in hot water after Google was felt to have got of lightly.Ahead of looming lending deadlines, Tesco has begun working on restructuring £1.4bn of its £17.5bn debt mountain. The grocer aims to repay £1.4bn in the next few months, the Sunday Telegraph said, as the risk of default on its borrowings climbed to the highest on record.With its own deadline of 2 February, Sainsbury's is under pressure from major investors to up its bid for Argos owner Home Retail but not over-pay for the deal. With Home Retail shareholders wanting around 220p a share, Sainsbury's management have been frustrated in their efforts to drum up support from their own backers due to wildly different views on valuation, according to sources cited by the Sunday Telegraph.Meanwhile, some of the pressure has dissipated in Shell's £36bn takeover of BG Group after news that a Brazil no longer plans to hike taxes on the oil sector. Fear of such a hike had led some institutional investors to plan to vote against the deal this Thursday, the Mail on Sunday reported.Activist investor Och-Ziff Capital has taken a stake in GlaxoSmithKline and is understood to have been adding to the heat on the drug group to replace chief executive Andrew Witty. The Sunday Times reported that the Manhattan firm's London arm has spoken to GS chairman Sir Philip Hampton, adding to pressure on Witty and finance director Simon Dingemans.The current state of high street banking IT systems is not up to scratch and the chief executives of Royal Bank of Scotland, HSBC and Barclays, as well as the heads of the Bank of England's regulatory arms, have been told to urgently begin addressing the matter from board level downwards. MP Andrew Tyrie, chairman of the Commons' Treasury Committee, said Andrew Bailey, Deputy Governor of the Bank of England and chief executive the bank's Prudential Regulation Authority (PRA) should lead official efforts to enforce banks to bring their computer systems up to scratch, the Sunday Times reported.Standard Chartered has found it difficult to find a suitable person to replace Sir John Peace as chairman. Major shareholders, cited by the Sunday Times, admitted the "modest salary" was a problem as "very few people who would take on the risk of being the chairman of a bank these days", heightened by regulations intended to make executives more accountable for scandals.Deutsche Bank may need to raise cash through a bond sale, or sale of its Postbank subsidiary, after analysts identified a €7bn capital hole in its accounts that will need to be filled by the end of next year. The lender's new chief executive, John Cryan, is looking to conserve cash by stopping the bank's dividend for the next two years, the Sunday Times said.Elsewhere in the banking sector, a pair of banks from Iran are in talks with UK regulators about reopening their doors to British businesses after lifting of sanctions against the Middle Eastern country, the Sunday Times revealed. Melli Bank and Persia International Bank have been given their license back by the Bank of England, while international banks around the world are preparing to re-establish links with Iranian counterparts using the Swift payments system.Profit warnings have soared to a post-crisis peak, according to figures compiled by Ernst & Young cited by the Sunday Telegraph. Data showed UK-listed companies have issued 313 downgrades over the past year, the most since 2008.Online grocer Ocado has attracted even more interest from short-selling hedge funds. Now the second most shorted company in the FTSE 350, Ocado's share price tumble was arrested by rumours of a takeover bid from online giant Amazon, but this has only served to dramatically increase short interest in the last week, said the Mail on Sunday.Imagination Technologies is poised to begin a major restructuring, including radical cost-cutting and the sale of its Pure digital radio arm. After a round of crisis talks with top institutional shareholders, chairman Bert Nordberg revealed plans to dispose of loss-making divisions as well as the possible sale of its corporate headquarters, the Sunday Times reported.Metro Bank will join its fellow UK challenger banks on the public markets with a £2bn initial public offer that flies in the face of the month's stock market turmoil. Metro, which in 2010 became the first new bank to launch in Britain for more than 100 years, has drawn up plans with its advisers to float £300m of its shares, the Mail on Sunday said, with a formal intention-to-float document expected this week.Mountain Warehouse could join it with its own £200m flotation, according to the Sunday Times. The retailer, which would be the first to IPO in London for almost a year, has appointed Rothschild to examine the move.Watkins Jones, the Welsh building and property management firm, has also begun working on a flotation with advisers at Zeus Capital. The company, which has an impressive client list and specialises in building student halls of residence, could be worth up to £300m, the Sunday Times said.
More News
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.